{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:21:12Z","timestamp":1762273272234,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00405-024-08545-9","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T15:25:34Z","timestamp":1713281134000},"page":"3929-3941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-angiogenesis agents plus chemoradiotherapy for locally advanced nasopharyngeal cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"281","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6768-8774","authenticated-orcid":false,"given":"Xueqing","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufei","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"8545_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J (2019) Nasopharyngeal carcinoma. Lancet 394:64\u201380","journal-title":"Lancet"},{"key":"8545_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"8545_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.6004\/jnccn.2022.0016","volume":"20","author":"JJ Caudell","year":"2022","unstructured":"Caudell JJ, Gillison ML, Maghami E, Spencer S, Pfister DG, Adkins D et al (2022) NCCN Guidelines(R) insights: head and neck cancers, version 1.2022. J Natl Compr Canc Netw 20:224\u2013234","journal-title":"J Natl Compr Canc Netw"},{"key":"8545_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.radonc.2014.11.039","volume":"114","author":"Y Bao","year":"2015","unstructured":"Bao Y, Peng F, Zhou QC, Yu ZH, Li JC, Cheng ZB et al (2015) Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer. Radiother Oncol 114:161\u2013166","journal-title":"Radiother Oncol"},{"key":"8545_CR5","first-page":"283","volume":"8","author":"J Wang","year":"2005","unstructured":"Wang J, Sun Y, Liu Y, Yu Q, Zhang Y, Li K et al (2005) Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 8:283\u2013290","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"8545_CR6","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/mt.2013.79","volume":"21","author":"C Cui","year":"2013","unstructured":"Cui C, Mao L, Chi Z, Si L, Sheng X, Kong Y et al (2013) A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther 21:1456\u20131463","journal-title":"Mol Ther"},{"key":"8545_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1179\/1973947815Y.0000000022","volume":"27","author":"BL Li","year":"2015","unstructured":"Li BL, Hu XL, Zhao XH, Sun HG, Zhou CY, Zhang Y (2015) Endostar combined with irinotecan\/calcium folinate\/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: a clinical study. J Chemother 27:301\u2013306","journal-title":"J Chemother"},{"key":"8545_CR8","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E et al (2023) Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 388:1657\u20131667","journal-title":"N Engl J Med"},{"key":"8545_CR9","first-page":"5565","volume":"60","author":"CG Lee","year":"2000","unstructured":"Lee CG, Heijn M, Di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C et al (2000) Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565\u20135570","journal-title":"Cancer Res"},{"key":"8545_CR10","first-page":"3374","volume":"59","author":"DH Gorski","year":"1999","unstructured":"Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM et al (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374\u20133378","journal-title":"Cancer Res"},{"key":"8545_CR11","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-07-1893","volume":"14","author":"C Timke","year":"2008","unstructured":"Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ et al (2008) Combination of vascular endothelial growth factor receptor\/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 14:2210\u20132219","journal-title":"Clin Cancer Res"},{"key":"8545_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1470-2045(11)70303-5","volume":"13","author":"NY Lee","year":"2012","unstructured":"Lee NY, Zhang Q, Pfister DG, Kim J, Garden AS, Mechalakos J et al (2012) Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol 13:172\u2013180","journal-title":"Lancet Oncol"},{"key":"8545_CR13","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.ijrobp.2019.11.371","volume":"106","author":"N Lee","year":"2020","unstructured":"Lee N, Harris J, Pfister DG, Kim J, Garden AS, Mechalakos JG et al (2020) Long-term update of a phase II study of concurrent chemoradiotherapy using radiation + bevacizumab (BV) for locally or regionally advanced nasopharyngeal cancer (NPC): RTOG 0615. Int J Radiat Oncol Biol Phys 106:1119","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"8545_CR14","first-page":"128","volume":"37","author":"Y Li","year":"2015","unstructured":"Li Y, Jin F, Wu W, Long J, Gong X, Chen G et al (2015) Clinical results of recombinant human endostatin combined with chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Zhi 37:128\u2013132","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"8545_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1","journal-title":"Syst Rev"},{"key":"8545_CR16","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","volume":"16","author":"M Al-Sarraf","year":"1998","unstructured":"Al-Sarraf M, Leblanc M, Giri PG, Fu KK, Cooper J, Vuong T et al (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16:1310\u20131317","journal-title":"J Clin Oncol"},{"key":"8545_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.radonc.2014.05.005","volume":"112","author":"F Wu","year":"2014","unstructured":"Wu F, Wang R, Lu H, Wei B, Feng G, Li G et al (2014) Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study. Radiother Oncol 112:106\u2013111","journal-title":"Radiother Oncol"},{"key":"8545_CR18","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182\u20131186","journal-title":"N Engl J Med"},{"key":"8545_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm0195-27","volume":"1","author":"J Folkman","year":"1995","unstructured":"Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27\u201331","journal-title":"Nat Med"},{"key":"8545_CR20","first-page":"365","volume":"19","author":"Q Jiang","year":"2013","unstructured":"Jiang Q, Huang JH, Hu B, He YF (2013) Efficacy of recombinant human endostatin combined with chemotherapy in the treatment of advanced nasopharyngeal carcinoma. Chin J Otorhinolaryngol-Skull Base Surg 19:365\u2013367","journal-title":"Chin J Otorhinolaryngol-Skull Base Surg"},{"key":"8545_CR21","first-page":"4290","volume":"37","author":"SQ Cao","year":"2017","unstructured":"Cao SQ, Zhu CY, Zhang K (2017) Effects of recombinant human endostatin combined with chemoradiotherapy on clinical efficacy, prognosis and serum vascular endothelial growth factor for nasopharyngeal carcinoma. Chin J Gerontol 37:4290\u20134292","journal-title":"Chin J Gerontol"},{"key":"8545_CR22","first-page":"111","volume":"6","author":"H Jiang","year":"2013","unstructured":"Jiang H, Si YF, Qin YD, Zhang Z, Huang B, Lu JL et al (2013) Clinical efficacy of Endostar combined with chemoradiotherapy in the treatment of nasopharyngeal carcinoma. Glob Tradit Chin Med 6:111\u2013112","journal-title":"Glob Tradit Chin Med"},{"key":"8545_CR23","first-page":"1252","volume":"24","author":"F Zhang","year":"2019","unstructured":"Zhang F, Yuan T, Gao M (2019) Efficacy of chemoradiotherapy combined with bevacizumab in patients with nasopharyngeal carcinoma: a comparative study. J BUON 24:1252\u20131258","journal-title":"J BUON"},{"key":"8545_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13014-022-02104-4","volume":"17","author":"Y Yin","year":"2022","unstructured":"Yin Y, Zhou Z, Li Z, Shen M, Qin Y, Yang C et al (2022) Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study. Radiat Oncol 17:135","journal-title":"Radiat Oncol"},{"key":"8545_CR25","doi-asserted-by":"publisher","first-page":"6293816","DOI":"10.1155\/2022\/6293816","volume":"2022","author":"D Zhan","year":"2022","unstructured":"Zhan D, Chen Z, Yang D, Wen J, Liu W (2022) Clinical effect of apatinib mesylate tablets combined with paclitaxel concurrent radiotherapy and chemotherapy in the first-line treatment of locally advanced nasopharyngeal carcinoma. Emerg Med Int 2022:6293816","journal-title":"Emerg Med Int"},{"key":"8545_CR26","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841\u2013844","journal-title":"Nature"},{"key":"8545_CR27","doi-asserted-by":"crossref","first-page":"E2900","DOI":"10.1073\/pnas.1419703112","volume":"112","author":"X Yang","year":"2015","unstructured":"Yang X, Zhang Y, Hosaka K, Andersson P, Wang J, Tholander F et al (2015) VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism and serves as a marker of poor prognosis for cancer patients. Proc Natl Acad Sci U S A 112:E2900-2909","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8545_CR28","first-page":"220","volume":"26","author":"C Irawan","year":"2022","unstructured":"Irawan C, Nufus H, Rachmadi L, Harimurti K, Munandar A, Yunus RE (2022) The relationship of vascular endothelial growth factor and osteopontin expression with 3-year progression-free survival of locally advanced nasopharyngeal cancer patients treated with platinum-based chemoradiation. Contemp Oncol (Pozn) 26:220\u2013228","journal-title":"Contemp Oncol (Pozn)"},{"key":"8545_CR29","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1002\/cncr.21790","volume":"106","author":"HQ Mai","year":"2006","unstructured":"Mai HQ, Zeng ZY, Zhang CQ, Feng KT, Guo X, Mo HY et al (2006) Elevated plasma big ET-1 is associated with distant failure in patients with advanced-stage nasopharyngeal carcinoma. Cancer 106:1548\u20131553","journal-title":"Cancer"},{"key":"8545_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2152\/jmi.53.20","volume":"53","author":"SR Doustjalali","year":"2006","unstructured":"Doustjalali SR, Yusof R, Govindasamy GK, Bustam AZ, Pillay B, Hashim OH (2006) Patients with nasopharyngeal carcinoma demonstrate enhanced serum and tissue ceruloplasmin expression. J Med Invest 53:20\u201328","journal-title":"J Med Invest"},{"key":"8545_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-0413-3","volume":"10","author":"WC Cho","year":"2004","unstructured":"Cho WC, Yip TT, Yip C, Yip V, Thulasiraman V, Ngan RK et al (2004) Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 10:43\u201352","journal-title":"Clin Cancer Res"},{"key":"8545_CR32","doi-asserted-by":"publisher","first-page":"1787854","DOI":"10.1155\/2022\/1787854","volume":"2022","author":"X Gong","year":"2022","unstructured":"Gong X, Wang L, Wu W, Li Y, Long J, Chen X et al (2022) The treatment combining antiangiogenesis with chemoradiotherapy impinges on the peripheral circulation vascular endothelial cells and therapeutic effect in the patients with locally advanced nasopharyngeal carcinoma. Biomed Res Int 2022:1787854","journal-title":"Biomed Res Int"},{"key":"8545_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2019.06.007","volume":"44","author":"Y Li","year":"2020","unstructured":"Li Y, Tian Y, Jin F, Wu W, Long J, Ouyang J et al (2020) A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update. Curr Probl Cancer 44:100492","journal-title":"Curr Probl Cancer"},{"key":"8545_CR34","volume-title":"Clinical observation of recombinant human vascular endostatin combined with chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma","author":"F Zhang","year":"2021","unstructured":"Zhang F (2021) Clinical observation of recombinant human vascular endostatin combined with chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma. Jishou University"},{"key":"8545_CR35","first-page":"1465","volume":"21","author":"WB Ding","year":"2014","unstructured":"Ding WB, Zhang PX, Shi L, Deng L, Zhang J, Yuan KH et al (2014) Efficacy of recombinant human endostatin combined with cisplatin plus 5-FU chemotherapy concurrent with radiotherapy for advanced nasopharyngeal carcinoma. Chin J Clin Oncol Rehabil 21:1465\u20131467","journal-title":"Chin J Clin Oncol Rehabil"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08545-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-024-08545-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08545-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T08:07:04Z","timestamp":1721722024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-024-08545-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["8545"],"URL":"https:\/\/doi.org\/10.1007\/s00405-024-08545-9","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"type":"print","value":"0937-4477"},{"type":"electronic","value":"1434-4726"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"assertion":[{"value":"20 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}